573 related articles for article (PubMed ID: 32150417)
1. Emerging Nano Drug Delivery Systems Targeting Cancer-Associated Fibroblasts for Improved Antitumor Effect and Tumor Drug Penetration.
Guo J; Zeng H; Chen Y
Mol Pharm; 2020 Apr; 17(4):1028-1048. PubMed ID: 32150417
[TBL] [Abstract][Full Text] [Related]
2. Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy.
Truffi M; Mazzucchelli S; Bonizzi A; Sorrentino L; Allevi R; Vanna R; Morasso C; Corsi F
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871158
[TBL] [Abstract][Full Text] [Related]
3. Comprehensively priming the tumor microenvironment by cancer-associated fibroblast-targeted liposomes for combined therapy with cancer cell-targeted chemotherapeutic drug delivery system.
Chen B; Dai W; Mei D; Liu T; Li S; He B; He B; Yuan L; Zhang H; Wang X; Zhang Q
J Control Release; 2016 Nov; 241():68-80. PubMed ID: 27641831
[TBL] [Abstract][Full Text] [Related]
4. Modulation of cancer-associated fibroblasts by nanodelivery system to enhance efficacy of tumor therapy.
Ai W; Liu T; Lv C; Feng X; Wang Q
Nanomedicine (Lond); 2023 Jun; 18(15):1025-1039. PubMed ID: 37584613
[TBL] [Abstract][Full Text] [Related]
5. Strategies of targeting pathological stroma for enhanced antitumor therapies.
Zhu Y; Yu F; Tan Y; Yuan H; Hu F
Pharmacol Res; 2019 Oct; 148():104401. PubMed ID: 31422113
[TBL] [Abstract][Full Text] [Related]
6. An exosomal strategy for targeting cancer-associated fibroblasts mediated tumors desmoplastic microenvironments.
Xue X; Wang X; Pang M; Yu L; Qian J; Li X; Tian M; Lu C; Xiao C; Liu Y
J Nanobiotechnology; 2024 Apr; 22(1):196. PubMed ID: 38644492
[TBL] [Abstract][Full Text] [Related]
7. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
8. miRNAs Delivery for Cancer-associated Fibroblasts' Activation and Drug Resistance in Cancer Microenvironment.
Anajafi S; Paryan M; Khoshnazar A; Soleimani M; Mohammadi-Yeganeh S
Endocr Metab Immune Disord Drug Targets; 2024; 24(3):333-347. PubMed ID: 37612874
[TBL] [Abstract][Full Text] [Related]
9. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways.
Yoshida GJ
J Exp Clin Cancer Res; 2020 Jun; 39(1):112. PubMed ID: 32546182
[TBL] [Abstract][Full Text] [Related]
10. Prior anti-CAFs break down the CAFs barrier and improve accumulation of docetaxel micelles in tumor.
Pang N; Li J; Sun A; Yang Z; Cheng S; Qi XR
Int J Nanomedicine; 2018; 13():5971-5990. PubMed ID: 30323586
[TBL] [Abstract][Full Text] [Related]
11. Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts.
Moatassim-Billah S; Duluc C; Samain R; Jean C; Perraud A; Decaup E; Cassant-Sourdy S; Bakri Y; Selves J; Schmid H; Martineau Y; Mathonnet M; Pyronnet S; Bousquet C
Oncotarget; 2016 Jul; 7(27):41584-41598. PubMed ID: 27177087
[TBL] [Abstract][Full Text] [Related]
12. Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy.
Mpekris F; Papageorgis P; Polydorou C; Voutouri C; Kalli M; Pirentis AP; Stylianopoulos T
J Control Release; 2017 Sep; 261():105-112. PubMed ID: 28662901
[TBL] [Abstract][Full Text] [Related]
13. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance.
Dzobo K; Dandara C
OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970
[TBL] [Abstract][Full Text] [Related]
14. Targeting nuclear receptors in cancer-associated fibroblasts as concurrent therapy to inhibit development of chemoresistant tumors.
Chan JSK; Sng MK; Teo ZQ; Chong HC; Twang JS; Tan NS
Oncogene; 2018 Jan; 37(2):160-173. PubMed ID: 28892046
[TBL] [Abstract][Full Text] [Related]
15. CAFs Homologous Biomimetic Liposome Bearing BET Inhibitor and Pirfenidone Synergistically Promoting Antitumor Efficacy in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Yu R; Zhao C; Liang J; Zhang Y; Su H; Zhao J; Wu H; Xu S; Zhang Z; Wang L; Zou X; Zhu Y; Zhang S; Lv Y
Adv Sci (Weinh); 2024 Jan; 11(1):e2305279. PubMed ID: 37968249
[TBL] [Abstract][Full Text] [Related]
16. Tumor-Associated Fibroblast-Targeting Nanoparticles for Enhancing Solid Tumor Therapy: Progress and Challenges.
Li W; Little N; Park J; Foster CA; Chen J; Lu J
Mol Pharm; 2021 Aug; 18(8):2889-2905. PubMed ID: 34260250
[TBL] [Abstract][Full Text] [Related]
17. Reversing activity of cancer associated fibroblast for staged glycolipid micelles against internal breast tumor cells.
Zhu Y; Yu F; Tan Y; Hong Y; Meng T; Liu Y; Dai S; Qiu G; Yuan H; Hu F
Theranostics; 2019; 9(23):6764-6779. PubMed ID: 31660067
[No Abstract] [Full Text] [Related]
18. Nanoparticle-based delivery systems modulate the tumor microenvironment in pancreatic cancer for enhanced therapy.
Jia M; Zhang D; Zhang C; Li C
J Nanobiotechnology; 2021 Nov; 19(1):384. PubMed ID: 34809634
[TBL] [Abstract][Full Text] [Related]
19. Emerging strategies against tumor-associated fibroblast for improved the penetration of nanoparticle into desmoplastic tumor.
Yunna C; Mengru H; Fengling W; Lei W; Weidong C
Eur J Pharm Biopharm; 2021 Aug; 165():75-83. PubMed ID: 33991610
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Takai K; Le A; Weaver VM; Werb Z
Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
